Luye Pharma

Executive Summary

Luye Pharma Group is a fully integrated, commercial-stage Chinese pharmaceutical company with a diversified portfolio spanning oncology, central nervous system (CNS) disorders, and cardiovascular diseases. Founded in 1994 and headquartered in Yantai, China, the company has grown to employ over 5,000 staff and operates a robust R&D, manufacturing, and commercial infrastructure. Luye has a leading position in the Chinese pharmaceutical market, with a focus on developing innovative and generic drugs. Its pipeline includes several late-stage candidates, particularly in CNS (e.g., novel antidepressants) and oncology (e.g., biosimilars and targeted therapies). The company is expanding globally through partnerships and its own commercial network, targeting markets in the US, Europe, and emerging regions. With strong revenue streams from existing products and a promising pipeline, Luye is well-positioned to capitalize on the growing demand for affordable, high-quality therapeutics in China and abroad. The company's integrated model and strategic focus on high-growth areas underpin its potential for sustained value creation.

Upcoming Catalysts (preview)

• Q2 2026NDA submission for LY03005 (depression) in China80% success
• Q3 2026Phase 3 data readout for LY01015 (oncology biosimilar) in China70% success
• Q4 2026Potential partnership for global commercialization of CNS pipeline60% success